Skip to main content
Equibles

VANGUARD CAPITAL MANAGEMENT LLC

Position in EXEL — Exelixis, Inc.

CIK 2100119 MALVERN, PA
Back to EXEL Full portfolio

Position in EXEL

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$595,843,746
+$112,945,923 QoQ
Shares Held
10,950,997
-2.7% QoQ
Ownership
4.42%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#6
of 756 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 0% Shared 0% None 100%

Common Shares in EXEL Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

VANGUARD CAPITAL MANAGEMENT LLC holds $43,385,068,026 across 465 Biotechnology names. EXEL ranks #11 (1.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 16,580,713 $8,236,137,568
2 REGN
Regeneron Pharmaceuticals, Inc.
 6,629,759 $4,133,919,926
3 ALNY
Alnylam Pharmaceuticals, Inc.
 6,029,478 $1,815,053,762
4 RVMD
Revolution Medicines, Inc.
 9,088,661 $1,702,124,432
5 MRNA
Moderna, Inc.
 23,208,792 $1,625,311,703
6 INCY
Incyte Corp
 11,024,289 $1,249,713,401
7 INSM
INSMED Inc
 9,790,865 $1,043,902,026
8 ROIV
Roivant Sciences Ltd.
 22,123,198 $782,939,977

All Filings in EXEL

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $595,843,746 10,950,997
2026-03-31 $482,897,823 11,258,984